Senti Biosciences Completes Merger With Up to $60 Million in Milestone Payments
Senti Biosciences completed its merger and arranged contingent value rights tied to SENTI-202, with potential payments of up to $60 million based on regulatory and sales milestones. It also acquired intellectual property and research assets for its Rett Syndrome and TIL programs.
Senti Biosciences completed its merger transaction and arranged contingent value rights tied to SENTI-202, with up to $60 million in potential payments based on regulatory and sales milestones. The company also acquired intellectual property and research assets for its Rett Syndrome and TIL program…